Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Frostman who wrote (9756)	6/17/1998 12:35:00 PM
From: VLAD	Read Replies (3) \| Respond to of 23519

FWIW, I just spoke to management and here is all the information I can offer: 1)Still no reason not to expect FDA approval this month. Unaware of any problems which would cause a rejection. 2)Vivus is fully aware of the shareholder sentiment and has no control of the stock price including the effects of the shorters. 3)The main focus now is on production (new plant) and marketing. vivus again has no control of external factors ie media hype of Viagra. 4)Vivus expects a loss this Q. A lot of product has been sold over seas but at a much lower profit. 5)Vivus looking very closely at costs and if it finds that the new sales reps are not effective they will seriously consider getting a large player to market/sell MUSE. 6)Vivus has discussed PR help from Astra. Astra is very conservative in advertising and may help out but no promises. 7)Vivus knows that things look ugly in terms of perception, stock price, Viagra--they are still confident that things will turn around in Q3 and Q4. They feel that US script numbers are the main focus and not international sales. 8)Vivus will be having a meeting on June 29th for institutional investors etc...Last I checked there was 50 institutions long on Vivus. I personally feel that Vivus will recover but in the short term the shorts will rule.

To: Frostman who wrote (9756)	6/17/1998 12:58:00 PM
From: DaiS	Respond to of 23519

I also sent E-mail to Astra on Monday with several questions, but not so far received reply, I gave my 'phone number - will try again. I also sent a follow up E-mail to SEC regarding the progress of its investigation of shorting of VVUS, and received same automated response to my first message of complaint to SEC. Anybody spare a couple of minutes to outline how FDA works in these circumstances. Is it just a NO or a YES? Or a qualified/conditional YES. Or if it is a NO do they then provide information on what precisely is required for future YES or do they just let the company stew? DaiS